EE05492B1 - Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral - Google Patents

Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral

Info

Publication number: EE05492B1
Authority: EE; Estonia
Prior art keywords: pharmaceutical compositions; related methods; amyloid; methods; diseases
Prior art date: 1999-06-01

Application number

EEP200100645A

Other languages

English (en)

Estonian (et)

Inventor

B. Schenk Dale

Original Assignee

Neuralab Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2000-06-01

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22475417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05492(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-01 Application filed by Neuralab Limited filed Critical Neuralab Limited

2003-02-17 Publication of EE200100645A publication Critical patent/EE200100645A/xx

2011-12-15 Publication of EE05492B1 publication Critical patent/EE05492B1/xx

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Food Science & Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Cell Biology (AREA)

EEP200100645A 1999-06-01 2000-06-01 Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral EE05492B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13701099P	1999-06-01	1999-06-01
PCT/US2000/015239 WO2000072876A2 (en)	1999-06-01	2000-06-01	Prevention and treatment of amyloidogenic disease

Publications (2)

Publication Number	Publication Date
EE200100645A EE200100645A (et)	2003-02-17
EE05492B1 true EE05492B1 (et)	2011-12-15

Family

ID=22475417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100645A EE05492B1 (et)	1999-06-01	2000-06-01	Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral

Country Status (31)

Country	Link
US (8)	US7977316B2 (xx)
EP (2)	EP1185296B1 (xx)
KR (3)	KR101142772B1 (xx)
CN (2)	CN101091795A (xx)
AT (1)	ATE495755T1 (xx)
AU (1)	AU5316300A (xx)
BG (1)	BG65756B1 (xx)
BR (1)	BR0011103A (xx)
CA (1)	CA2375104C (xx)
CY (1)	CY1111639T1 (xx)
CZ (1)	CZ302971B6 (xx)
DE (1)	DE60045550D1 (xx)
EA (1)	EA200101250A1 (xx)
EE (1)	EE05492B1 (xx)
ES (2)	ES2445799T3 (xx)
HK (1)	HK1045117B (xx)
HR (1)	HRP20010893A2 (xx)
HU (1)	HU229986B1 (xx)
IL (3)	IL146563A0 (xx)
IS (1)	IS2925B (xx)
MX (1)	MXPA01012293A (xx)
NO (1)	NO20015758L (xx)
NZ (2)	NZ556622A (xx)
PL (1)	PL202217B1 (xx)
PT (1)	PT1185296E (xx)
SG (2)	SG147275A1 (xx)
SK (1)	SK288207B6 (xx)
TR (1)	TR200103469T2 (xx)
UA (1)	UA81216C2 (xx)
WO (1)	WO2000072876A2 (xx)
ZA (1)	ZA200109662B (xx)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
EP2204186B1 (en)	1999-02-17	2016-04-06	CSL Limited	Immunogenic complexes and methods relating thereto
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
CN1414976A (zh)	1999-12-08	2003-04-30	明德塞特生物制药(美国)公司	作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
GB0000891D0 (en)	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (en)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
WO2002003911A2 (en)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention and treatment of alzheimer's disease
AU2007200047B2 (en) *	2000-07-07	2009-11-26	Bioarctic Neuroscience Ab	Prevention and treatment of Alzheimer's disease
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
ATE420114T1 (de)	2001-04-30	2009-01-15	Lilly Co Eli	Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
WO2002088307A2 (en)	2001-04-30	2002-11-07	Eli Lilly And Company	Humanized antibodies
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DK1944040T3 (da)	2001-08-17	2012-10-29	Univ Washington	Analysefremgangsmåde for Alzheimers sygdom
US20050227941A1 (en) *	2001-12-17	2005-10-13	Karen Duff	Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US20060210555A1 (en) *	2001-12-21	2006-09-21	Antigenics, Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2493119A1 (en) *	2002-07-17	2004-01-22	Mindset Biopharmaceuticals Usa Inc.	Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US20070213512A1 (en) *	2002-10-01	2007-09-13	Krafft Grant A	Amyloid beta peptide analogs and assemblies thereof
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en)	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de)	2003-02-10	2010-06-15	Applied Molecular Evolution	Abeta-bindende moleküle
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
ES2246177B1 (es) *	2003-05-08	2007-03-01	Universidad De Zaragoza.	Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en)	2003-05-19	2017-07-03	Prothena Biosciences Ltd	Truncated fragments of alpha synuclein in Lewy body disease
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005047860A2 (en)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Antibodies to alpha-synuclein
EP1717250A4 (en) *	2004-02-20	2008-10-01	Immuno Biological Lab Co Ltd	MONOCLONAL ANTIBODY AND ITS USE
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
EP1838854B1 (en)	2004-12-15	2012-10-31	Janssen Alzheimer Immunotherapy	Antibodies that recognize Beta Amyloid Peptide
JP2008523815A (ja)	2004-12-15	2008-07-10	エランファーマインターナショナルリミテッド	認知の改善における使用のためのヒト化アミロイドβ抗体
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
SI2289909T1 (sl) *	2005-11-30	2015-03-31	Abbvie Inc.	Presejalni postopek, postopek za ÄŤiĹˇÄŤenje nedifuzibilnih Abeta-oligomerov, selektivna protitelesa proti nedifuzibilnim Abeta-oligomerom in postopek za izdelavo protiteles
EP1976877B2 (en)	2005-11-30	2016-10-05	AbbVie Inc.	Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en)	2005-11-30	2019-10-29	Abbott Laboratories	Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP2004688B2 (en)	2006-03-23	2014-03-05	BioArtic Neuroscience AB	Improved protofibril selective antibodies and the use thereof
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
JP2010504089A (ja) *	2006-09-25	2010-02-12	ユニフェルジテイト・マーストリヒト	心不全を発生させる危険がある被検者を診断および／または処置するための手段および方法
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
ES2635317T3 (es)	2007-01-05	2017-10-03	University Of Zurich	Anticuerpo anti-beta-amiloide y sus usos
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2118300B1 (en)	2007-02-23	2015-05-27	Prothena Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
EP3067066B1 (en)	2007-02-23	2019-03-27	Prothena Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
TR201802286T4 (tr) *	2007-04-20	2018-03-21	The Chemo Sero Therapeutic Res Institute	Peptidle bağışıklık yanıtının arttırılması için yöntem.
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
EP2175879A4 (en) *	2007-08-09	2010-09-22	Sylvan Pharmaceuticals Pty Ltd	TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
TR201901497T4 (tr)	2008-04-29	2019-02-21	Bioarctic Ab	Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN102317316B (zh)	2008-12-19	2014-08-13	帕尼玛制药股份公司	人抗α突触核蛋白自身抗体
CN106397588B (zh)	2010-02-26	2020-09-08	生命北极神经科学公司	原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
KR20110111594A (ko) *	2010-04-05	2011-10-12	서울대학교산학협력단	알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
WO2011151833A1 (en) *	2010-06-03	2011-12-08	Ramot At Tel-Aviv University Ltd.	Methods of treating diabetes and compositions capable of same
CN102311499A (zh) *	2010-07-09	2012-01-11	博生吉医药科技(苏州)有限公司	一种癌症治疗用人源化单克隆抗体及其制备及应用
WO2012020124A1 (en)	2010-08-12	2012-02-16	Ac Immune S.A.	Vaccine engineering
MX358739B (es)	2010-08-14	2018-09-03	Abbvie Inc Star	Proteinas de union a amiloide beta.
AU2011322553B2 (en)	2010-10-26	2015-07-02	Ac Immune S.A.	Liposome-based construct comprising a peptide modified through hydrophobic moieties
CN105693865B (zh) *	2011-06-01	2020-07-17	厦门大学	包含白喉毒素无毒突变体crm197或其片段的融合蛋白
MX357193B (es)	2011-06-23	2018-06-29	Univ Zuerich	Moleculas de union anti-alfa sinucleina.
RS53496B1 (sr)	2011-10-04	2015-02-27	Affiris Ag	POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP3865510A3 (en)	2014-07-10	2021-10-27	BioArctic AB	Improved a-beta protofibril binding antibodies
CN105616405B (zh) *	2014-11-05	2021-05-07	中国人民解放军第三军医大学第三附属医院	依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US10464999B2 (en)	2015-01-28	2019-11-05	Prothena Biosciences Limited	Anti-transthyretin antibodies
US9879080B2 (en)	2015-01-28	2018-01-30	Prothena Biosciences Limited	Anti-transthyretin antibodies
US10633433B2 (en)	2015-01-28	2020-04-28	Prothena Biosciences Limited	Anti-transthyretin antibodies
EP3070096A1 (en) *	2015-03-19	2016-09-21	Ludwig-Maximilians-Universität München	A peptide or collection of peptides derived from amyloid precursor protein
JP7452829B2 (ja)	2015-11-09	2024-03-19	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータのエピトープおよびそれに対する抗体
US10774120B2 (en) *	2015-11-09	2020-09-15	The University Of British Columbia	Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004482A1 (en)	2015-11-09	2017-05-18	Neil R. Cashman	N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10265497B2 (en)	2015-11-24	2019-04-23	Massachusetts Institute Of Technology	Systems and methods for treating dementia
AU2017299858B2 (en)	2016-07-18	2024-07-25	Promis Neurosciences, Inc.	Antibodies to Amyloid beta
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
KR102674264B1 (ko)	2016-11-17	2024-06-13	코그니토 쎄라퓨틱스, 인코포레이티드	시각 자극을 통한 신경 자극 방법 및 시스템
US11530257B2 (en)	2017-06-29	2022-12-20	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
CA3070446A1 (en)	2017-07-25	2019-01-31	Immutics, Inc.	Treating cancer by blocking the interaction of tim-3 and its ligand
US11382974B2 (en) *	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
EP3672631B9 (en)	2017-08-22	2023-06-28	Biogen MA Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2019071206A1 (en)	2017-10-06	2019-04-11	Prothena Biosciences Limited	METHODS OF DETECTING TRANSTHYRETIN
CN111315213B (zh)	2017-10-06	2023-09-12	普罗塞纳生物科学有限公司	抗甲状腺素运载蛋白抗体
US10960225B2 (en)	2017-10-10	2021-03-30	Massachusetts Institute Of Technology	Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
WO2019074637A1 (en)	2017-10-10	2019-04-18	Massachusetts Institute Of Technology	SYSTEMS AND METHODS FOR PREVENTION, MITIGATION AND / OR TREATMENT OF DEMENTIA
CN111433223B (zh)	2017-11-29	2024-08-27	诺和诺德A/S（股份有限公司）	抗甲状腺素运载蛋白单克隆抗体的冻干制剂
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
CN115359999A (zh)	2018-11-02	2022-11-18	台达电子企业管理（上海）有限公司	变压器模块及功率模块
WO2020094883A1 (en) *	2018-11-09	2020-05-14	Neurimmune Ag	Patient-derived amyloid xenograft non-human animal model
WO2020160156A2 (en)	2019-01-30	2020-08-06	Immutics, Inc.	Anti-gal3 antibodies and uses thereof
KR102135130B1 (ko) *	2019-02-15	2020-07-17	충북대학교 산학협력단	트랜스타이레틴 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
KR20230016186A (ko)	2020-05-26	2023-02-01	트루바인딩 아이엔씨.	갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
EP4236988A4 (en) *	2020-10-30	2024-10-30	Rush University Medical Center	INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CN115475247B (zh) *	2021-06-16	2024-02-20	厦门大学	β2-微球蛋白或其抑制剂的制药用途
CA3239708A1 (en) *	2021-12-03	2023-06-08	Aubin MICHALON	Novel potency assay for antibody-based drugs and useful means therefor
TWI824398B (zh) *	2022-01-27	2023-12-01	慈濟學校財團法人慈濟大學	一種肌動蛋白重組調節物之抑制劑用於製備治療睡眠剝奪引起之記憶退化之藥物之用途
CN120457342A (zh) *	2022-12-05	2025-08-08	神经免疫有限公司	环状化合物及环状化合物在用于检测抗体的测定中的用途

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US573547A (en) *		1896-12-22		smith
US73655A (en) *		1868-01-21		Improvement in safety-pockets
US14692A (en) *		1856-04-15		Improved diaphragm fluid-meter
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4443427A (en) *	1982-06-21	1984-04-17	Sidney Farber Cancer Institute, Inc.	Monoclonal antibody
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
US5208036A (en)	1985-01-07	1993-05-04	Syntex (U.S.A.) Inc.	N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001597A1 (en) *	1985-09-19	1987-04-26	Toray Industries, Inc.	beta2-MICROGLOBULIN-REMOVING COLUMN
US4641473A (en) *	1985-12-23	1987-02-10	Trezza Ronald F	Clip construction for wall arrangement
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5231170A (en)	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
GB8625435D0 (en) *	1986-10-23	1986-11-26	Erba Farmitalia	Human apolipoprotein ai
US5220013A (en)	1986-11-17	1993-06-15	Scios Nova Inc.	DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) *	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5290762A (en) *	1986-12-24	1994-03-01	John Lezdey	Treatment of inflammation
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP0832981A1 (en)	1987-02-17	1998-04-01	Pharming B.V.	DNA sequences to target proteins to the mammary gland for efficient secretion
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5571499A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) *	1987-06-24	1997-06-24	Autoimmune, Inc.	Prevention of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en)	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
US5869054A (en) *	1987-06-24	1999-02-09	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of autoantigens
AU632991B2 (en)	1987-06-24	1993-01-21	Autoimmune, Inc.	Treatment of autoimmune diseases by oral administration of autoantigens
US5571500A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5645820A (en) *	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en) *	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
CA1339014C (en)	1987-10-08	1997-03-25	Ronald E. Majocha	Antibodies to a4 amyloid peptide
US5231000A (en)	1987-10-08	1993-07-27	The Mclean Hospital	Antibodies to A4 amyloid peptide
AU2728588A (en)	1987-10-23	1989-05-23	Genetics Institute Inc.	Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5266561A (en) *	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
WO1989006689A1 (en)	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic constructs containing the alzheimer brain amyloid gene
US5785973A (en) *	1988-02-01	1998-07-28	Praxis Biologics, Inc.	Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2055785T3 (es)	1989-01-17	1994-09-01	Eniricerche Spa	Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
AU5525090A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Monoclonal antibody to amyloid peptide
AU5439790A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5262303A (en) *	1989-10-13	1993-11-16	Trustees Of Boston University	Ligand/anti-ligand assays for adherent proteins
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
EP0506785B1 (en)	1989-12-20	2000-03-15	Autoimmune, Inc.	Improved treatment of autoimmune diseases by aerosol administration of auto antigens
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
HUT61896A (en)	1990-03-02	1993-03-29	Autoimmune Inc	Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
EP0451700A1 (en)	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
EP0527823A1 (en)	1990-04-24	1993-02-24	The Regents Of The University Of California	Purification, detection and methods of use of protease nexin-2
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
EP0526511B1 (en)	1990-04-27	1997-05-28	MCMICHAEL, John	Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU8081491A (en)	1990-06-01	1991-12-31	Cetus Corporation	Compositions and methods for identifying biologically active molecules
US5593970A (en)	1990-06-11	1997-01-14	Biochem Pharma Inc.	Heterocyclic anthracycline analogs
JPH06507782A (ja)	1990-06-15	1994-09-08	サイオス　ノバ　インコーポレイテッド	アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
CA2109602C (en)	1990-07-10	2002-10-01	Gregory P. Winter	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5780587A (en) *	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2092823A1 (en)	1990-09-28	1992-03-29	Barry D. Greenberg	Transgenic animals with alzheimer's amyloid precursor gene
ATE319474T1 (de)	1990-10-15	2006-03-15	Autoimmune Inc	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
CA2372251A1 (en)	1991-01-21	1992-08-06	Michael John Mullan	Test and model for alzheimer's disease
US5192753A (en) *	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
US5672805A (en)	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) *	1991-08-13	1995-07-18	Regents Of The University Of Minnesota	Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
US5770358A (en)	1991-09-18	1998-06-23	Affymax Technologies N.V.	Tagged synthetic oligomer libraries
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
DK0620849T3 (da)	1992-01-07	2003-10-20	Elan Pharm Inc	Transgene dyremodeller for Alzheimer's sygdom
US5679348A (en) *	1992-02-03	1997-10-21	Cedars-Sinai Medical Center	Immunotherapy for recurrent HSV infections
EP0625910B1 (en)	1992-02-11	2003-07-23	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Dual carrier immunogenic construct
US5314813A (en)	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
DE69332518T2 (de)	1992-02-28	2003-09-04	Autoimmune Inc	Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DK0640131T3 (da) *	1992-03-17	1999-11-01	Novartis Ag	Gensplejsere antistoffer
EP0561087B1 (en)	1992-03-20	1999-08-04	N.V. Innogenetics S.A.	Mutated form of the beta-amyloid precursor protein gene
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5441870A (en)	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
GB9209118D0 (en)	1992-04-28	1992-06-10	Sb 120 Amsterdam Bv	Vaccine compositions
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) *	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en)	1992-07-13	1994-01-20	The Children's Medical Center Corporation	SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
EP0863211A1 (en)	1992-07-31	1998-09-09	Medeva Holdings B.V.	Expression of recombinant fusion proteins in attenuated bacteria
US5958883A (en) *	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
DE69333087T2 (de)	1992-10-01	2004-05-06	The Trustees Of Columbia University In The City Of New York	Komplexe kombinatorische chemische banken, die mit markierungen versehen sind
US5605811A (en)	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
DE69333144T2 (de) *	1992-10-26	2004-05-19	Elan Pharmaceuticals, Inc., San Francisco	Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
US5674703A (en)	1992-12-02	1997-10-07	Woo; Savio L. C.	Episomal vector systems and related methods
DE69329974T2 (de)	1992-12-04	2001-07-19	Medical Research Council, London	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0683234B2 (en)	1993-01-25	2007-06-06	Takeda Chemical Industries, Ltd.	Antibody against beta-amyloid or their derivative and use thereof
US5955317A (en) *	1993-01-25	1999-09-21	Takeda Chemical Industries, Ltd.	Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (en)	1993-02-22	1994-08-23	Gerald W. Becker	Pharmaceutical screens and antibodies
CN1087176C (zh)	1993-03-23	2002-07-10	史密斯克莱·比奇曼生物公司	含有3－o脱酰基单磷酰脂a的疫苗制剂
US5643562A (en) *	1993-03-29	1997-07-01	Queen's University Of Kingston	Method for treating amyloidosis
ES2180576T3 (es) *	1993-04-27	2003-02-16	United Biomedical Inc	Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
WO1994028412A1 (en)	1993-05-28	1994-12-08	The Miriam Hospital	Composition and method for in vivo imaging of amyloid deposits
CA2168459C (en)	1993-07-30	2002-10-01	Mohammed Anjam Khan	Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
EP0666566B1 (en) *	1993-08-10	2001-11-14	Sony Corporation	Recording and/or reproduction apparatus
US5728385A (en) *	1993-08-12	1998-03-17	Classen Immunotherapies, Inc.	Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
WO1995005853A1 (en)	1993-08-26	1995-03-02	The Regents Of The University Of California	Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
ES2318848T3 (es)	1993-09-14	2009-05-01	Pharmexa Inc.	Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
US5446650A (en)	1993-10-12	1995-08-29	Tektronix, Inc.	Logic signal extraction
EP0728215B1 (en)	1993-10-20	2002-02-20	Duke University	METHOD OF BINDING MATERIAL TO THE Beta-AMYLOID PEPTIDE
BR9407947A (pt)	1993-11-02	1996-11-26	Affymax Tech Nv	Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
US5744368A (en)	1993-11-04	1998-04-28	Research Foundation Of State University Of New York	Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5434170A (en) *	1993-12-23	1995-07-18	Andrulis Pharmaceuticals Corp.	Method for treating neurocognitive disorders
US5914349A (en)	1994-01-10	1999-06-22	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ATE278023T1 (de) *	1994-01-27	2004-10-15	Univ Minnesota	Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1995020979A1 (en) *	1994-02-03	1995-08-10	The Picower Institute For Medical Research	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
JPH10500112A (ja)	1994-05-06	1998-01-06	ファーマコピーア，インコーポレイテッド	組合せジヒドロベンゾピランライブラリー
WO1995031996A1 (en) *	1994-05-25	1995-11-30	Milkhaus Lab	Materials and methods for treatment of plaquing diseases
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en)	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US6417178B1 (en)	1994-07-19	2002-07-09	University Of Pittsburgh	Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en)	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
CA2214247C (en) *	1995-03-14	2004-02-10	Praecis Pharmaceuticals Incorporated	Modulators of amyloid aggregation
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
DE19518147B4 (de) *	1995-05-17	2013-09-05	Günther Nath	UV-stabiler Flüssigkeitslichtleiter
WO1996039176A1 (en)	1995-06-05	1996-12-12	Brigham & Women's Hospital	USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US5948763A (en) *	1995-06-07	1999-09-07	New York University	Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
ES2174027T3 (es) *	1995-06-30	2002-11-01	American Cyanamid Co	Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
US5671500A (en) *	1995-08-07	1997-09-30	Balk; Brett	Overhead door spring shield system
WO1997006809A1 (en)	1995-08-21	1997-02-27	Cytrx Corporation	Compositions and methods for growth promotion
JP3713074B2 (ja)	1995-08-30	2005-11-02	栄研化学株式会社	血清アミロイドａを認識するモノクローナル抗体
WO1997010505A1 (en) *	1995-09-14	1997-03-20	The Regents Of The University Of California	ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿
US5750361A (en)	1995-11-02	1998-05-12	The Regents Of The University Of California	Formation and use of prion protein (PRP) complexes
WO1997017614A1 (en)	1995-11-10	1997-05-15	Elan Corporation, Plc	Peptides which enhance transport across tissues and methods of identifying and using the same
AU1072897A (en)	1995-12-12	1997-07-03	Karolinska Innovations Ab	Peptide binding the klvff-sequence of amyloid beta
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
US6150091A (en) *	1996-03-06	2000-11-21	Baylor College Of Medicine	Direct molecular diagnosis of Friedreich ataxia
JP4229341B2 (ja)	1996-03-23	2009-02-25	財団法人阪大微生物病研究会	破傷風毒素の機能的フラグメント抗原及び破傷風ワクチン
CA2183901A1 (en)	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6057367A (en) *	1996-08-30	2000-05-02	Duke University	Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) *	1996-11-05	2004-09-28	The Regents Of The University Of California	Somatic cells with ablated PrP gene and methods of use
ATE441432T1 (de)	1997-03-10	2009-09-15	Ottawa Hospital Res Inst	Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
CN1138579C (zh)	1997-03-31	2004-02-18	阿尔萨公司	可扩散植入的释放系统
PT994728E (pt) *	1997-04-09	2008-11-11	Intellect Neurosciences Inc	Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US5972269A (en)	1997-06-17	1999-10-26	Taurus International Manufacturing, Inc.	Method of forming cavities in ceramic or metal injection molded parts using a fugitive core
WO1999000150A2 (en)	1997-06-27	1999-01-07	Regents Of The University Of California	Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7078191B1 (en)	1997-08-01	2006-07-18	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6923964B1 (en) *	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TR200001596T2 (tr)	1997-12-03	2000-12-21	Fujisawa Pharmaceutical Co., Ltd.	Yumuşak hap ilaç ve bunun üretim usulü
JP2002511385A (ja)	1997-12-03	2002-04-16	ニューララブリミテッド	アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
FR2777015B3 (fr)	1998-02-23	2000-09-15	Financ De Biotechnologie	Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
NO314086B1 (no)	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
JP2003532618A (ja)	1998-05-19	2003-11-05	イエダリサーチアンドデベロプメントカンパニイリミテッド	細胞、神経系−特異的抗原およびそれらの用途
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
WO1999060024A1 (en)	1998-05-21	1999-11-25	The University Of Tennessee Research Corporation	Methods for amyloid removal using anti-amyloid antibodies
DE69915697T2 (de)	1999-01-19	2005-01-13	Pharmacia & Upjohn Co., Kalamazoo	Packungsverfahren für Oxidationsempfindliche Medikamente
JP2002535289A (ja) *	1999-01-22	2002-10-22	ドウアリング，マシユー・ジヨン	神経疾患のワクチン媒介治療
AR024558A1 (es)	1999-06-01	2002-10-16	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
JP5249482B2 (ja)	1999-06-16	2013-07-31	ボストン・バイオメデイカル・リサーチ・インステイテユート	インビボのβ−アミロイドレベルの免疫学的制御
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
AU784312B2 (en)	1999-11-29	2006-03-09	Bellus Health (International) Limited	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CN1414976A (zh)	1999-12-08	2003-04-30	明德塞特生物制药(美国)公司	作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
EE200200444A (et)	2000-02-21	2003-12-15	Pharmexa A/S	Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (en)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
CA2408925A1 (en)	2000-05-22	2001-11-29	New York University	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
WO2002003911A2 (en)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention and treatment of alzheimer's disease
EP1172378A1 (en)	2000-07-12	2002-01-16	Richard Dr. Dodel	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) *	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
IT1319277B1 (it)	2000-10-24	2003-09-26	Chiesi Farma Spa	Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en)	2000-10-26	2001-11-25	Marikovsky Moshe	Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
WO2002060920A2 (en) *	2000-12-27	2002-08-08	Board Of Regents, University Of Texas System	Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
US20020147882A1 (en) *	2001-04-10	2002-10-10	Pua Khein Seng	Universal serial bus flash memory storage device
EP1251138B1 (en) *	2001-04-19	2006-07-26	Hermann Dr. Schätzl	Prion protein dimers useful for vaccination
AU2002345843A1 (en) *	2001-06-22	2003-01-08	Panacea Pharmaceuticals, Inc.	Compositions and methods for preventing protein aggregation in neurodegenerative diseases
ES2435741T3 (es) *	2001-08-06	2013-12-23	Kao Corporation	Composición acondicionadora
JP2006508045A (ja) *	2002-07-30	2006-03-09	エスペリオンセラピューティクス，インコーポレイテッド	ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法
WO2010033861A1 (en) *	2008-09-18	2010-03-25	Cedars-Sinai Medical Center	Optical method for the detection of alzheimer's disease

2000
- 2000-01-06 UA UA2001118223A patent/UA81216C2/uk unknown
- 2000-06-01 EA EA200101250A patent/EA200101250A1/ru unknown
- 2000-06-01 CN CNA2007101032809A patent/CN101091795A/zh active Pending
- 2000-06-01 ES ES10182493.6T patent/ES2445799T3/es not_active Expired - Lifetime
- 2000-06-01 DE DE60045550T patent/DE60045550D1/de not_active Expired - Lifetime
- 2000-06-01 PT PT00938075T patent/PT1185296E/pt unknown
- 2000-06-01 BR BR0011103-1A patent/BR0011103A/pt not_active Application Discontinuation
- 2000-06-01 ES ES00938075T patent/ES2362029T3/es not_active Expired - Lifetime
- 2000-06-01 MX MXPA01012293A patent/MXPA01012293A/es active IP Right Grant
- 2000-06-01 NZ NZ556622A patent/NZ556622A/en not_active IP Right Cessation
- 2000-06-01 SG SG200401386-8A patent/SG147275A1/en unknown
- 2000-06-01 IL IL14656300A patent/IL146563A0/xx unknown
- 2000-06-01 AT AT00938075T patent/ATE495755T1/de active
- 2000-06-01 CA CA2375104A patent/CA2375104C/en not_active Expired - Fee Related
- 2000-06-01 KR KR1020107019313A patent/KR101142772B1/ko not_active Expired - Lifetime
- 2000-06-01 HU HU0201205A patent/HU229986B1/hu unknown
- 2000-06-01 EP EP00938075A patent/EP1185296B1/en not_active Expired - Lifetime
- 2000-06-01 EE EEP200100645A patent/EE05492B1/xx unknown
- 2000-06-01 WO PCT/US2000/015239 patent/WO2000072876A2/en not_active Ceased
- 2000-06-01 HK HK02106697.1A patent/HK1045117B/en not_active IP Right Cessation
- 2000-06-01 SK SK1718-2001A patent/SK288207B6/sk not_active IP Right Cessation
- 2000-06-01 PL PL352717A patent/PL202217B1/pl unknown
- 2000-06-01 SG SG200401385-0A patent/SG147274A1/en unknown
- 2000-06-01 CZ CZ20014154A patent/CZ302971B6/cs not_active IP Right Cessation
- 2000-06-01 CN CN00808358A patent/CN1377278A/zh active Pending
- 2000-06-01 TR TR2001/03469T patent/TR200103469T2/xx unknown
- 2000-06-01 NZ NZ587223A patent/NZ587223A/en not_active IP Right Cessation
- 2000-06-01 HR HR20010893A patent/HRP20010893A2/hr not_active Application Discontinuation
- 2000-06-01 AU AU53163/00A patent/AU5316300A/en not_active Abandoned
- 2000-06-01 KR KR1020097012115A patent/KR20090071673A/ko not_active Withdrawn
- 2000-06-01 KR KR1020017015508A patent/KR100930559B1/ko not_active Expired - Lifetime
- 2000-06-01 EP EP10182493.6A patent/EP2364719B1/en not_active Expired - Lifetime
2001
- 2001-11-19 IL IL146563A patent/IL146563A/en not_active IP Right Cessation
- 2001-11-21 IS IS6170A patent/IS2925B/is unknown
- 2001-11-23 BG BG106140A patent/BG65756B1/bg unknown
- 2001-11-23 ZA ZA200109662A patent/ZA200109662B/en unknown
- 2001-11-26 NO NO20015758A patent/NO20015758L/no not_active Application Discontinuation
2007
- 2007-08-20 US US11/842,046 patent/US7977316B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/842,052 patent/US8124081B2/en not_active Expired - Fee Related
2009
- 2009-03-13 US US12/403,414 patent/US20090285822A1/en not_active Abandoned
- 2009-03-30 US US12/414,347 patent/US20090285809A1/en not_active Abandoned
2010
- 2010-07-22 IL IL207166A patent/IL207166A/en not_active IP Right Cessation
- 2010-11-05 US US12/940,750 patent/US20110064734A1/en not_active Abandoned
2011
- 2011-02-23 US US13/033,336 patent/US20110177066A1/en not_active Abandoned
- 2011-02-23 US US13/033,418 patent/US20110182893A1/en not_active Abandoned
- 2011-04-18 US US13/088,983 patent/US20110287049A1/en not_active Abandoned
- 2011-04-19 CY CY20111100403T patent/CY1111639T1/el unknown

Also Published As

Publication number	Publication date
HK1160392A1 (en)	2012-08-17
CN1377278A (zh)	2002-10-30
UA81216C2 (en)	2007-12-25
HU229986B1 (en)	2015-04-28
IL146563A0 (en)	2002-07-25
US20110182893A1 (en)	2011-07-28
AU5316300A (en)	2000-12-18
HUP0201205A3 (en)	2004-07-28
NZ587223A (en)	2011-12-22
IL146563A (en)	2010-11-30
WO2000072876A3 (en)	2001-05-03
US20110287049A1 (en)	2011-11-24
CZ20014154A3 (cs)	2002-11-13
CA2375104A1 (en)	2000-12-07
KR20100099355A (ko)	2010-09-10
IS6170A (is)	2001-11-21
CA2375104C (en)	2013-12-24
HK1045117B (en)	2011-08-05
CZ302971B6 (cs)	2012-01-25
BG106140A (bg)	2002-08-30
US20080248023A1 (en)	2008-10-09
CN101091795A (zh)	2007-12-26
WO2000072876A2 (en)	2000-12-07
SK288207B6 (sk)	2014-07-02
EP2364719A1 (en)	2011-09-14
KR20090071673A (ko)	2009-07-01
DE60045550D1 (de)	2011-03-03
NZ556622A (en)	2009-03-31
NO20015758L (no)	2002-01-30
US20110177066A1 (en)	2011-07-21
HUP0201205A2 (en)	2002-08-28
IL207166A (en)	2013-11-28
ZA200109662B (en)	2003-05-23
HK1045117A1 (en)	2002-11-15
US7977316B2 (en)	2011-07-12
US20110064734A1 (en)	2011-03-17
EP1185296B1 (en)	2011-01-19
ES2362029T3 (es)	2011-06-27
SG147274A1 (en)	2008-11-28
BR0011103A (pt)	2002-03-19
KR100930559B1 (ko)	2009-12-09
ATE495755T1 (de)	2011-02-15
TR200103469T2 (tr)	2002-05-21
EP2364719B1 (en)	2013-11-13
CY1111639T1 (el)	2015-10-07
PL352717A1 (en)	2003-09-08
PL202217B1 (pl)	2009-06-30
EE200100645A (et)	2003-02-17
BG65756B1 (bg)	2009-10-30
ES2445799T3 (es)	2014-03-05
KR101142772B1 (ko)	2012-05-18
US8124081B2 (en)	2012-02-28
SG147275A1 (en)	2008-11-28
IS2925B (is)	2015-06-15
EA200101250A1 (ru)	2002-06-27
US20090285822A1 (en)	2009-11-19
SK17182001A3 (sk)	2002-09-10
KR20020025884A (ko)	2002-04-04
EP1185296A2 (en)	2002-03-13
MXPA01012293A (es)	2002-11-07
US20080248029A1 (en)	2008-10-09
HRP20010893A2 (en)	2003-04-30
PT1185296E (pt)	2011-04-19
US20090285809A1 (en)	2009-11-19
NO20015758D0 (no)	2001-11-26
IL207166A0 (en)	2010-12-30

Publication	Publication Date	Title
EE05492B1 (et)	2011-12-15	Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral
ATE153534T1 (de)	1997-06-15	Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
CY1105922T1 (el)	2011-04-06	Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
DE69831971D1 (de)	2006-03-02	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
CY1109368T1 (el)	2014-07-02	Προληψη και θεραπεια αμυλοειδογονου νοσου
PT721449E (pt)	2002-06-28	Inibidores da producao da proteina beta-amiloide
EA200501560A1 (ru)	2006-04-28	Предотвращение и терапия амилоидогенной болезни
DE602004021797D1 (de)	2009-08-13	Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
DE69526216D1 (de)	2002-05-08	Antifungaleverfahren und mitteln
ATE162075T1 (de)	1998-01-15	Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DK2172208T3 (da)	2013-10-28	Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
NO20001869L (no)	2000-06-14	FremgangsmÕte for behandling av Alzheimers sykdom
TR200000455T2 (tr)	2000-09-21	Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DK0821969T3 (da)	2007-03-26	Medicinsk sammensætning omfattende TCF-II
ES2150418T3 (es)	2000-12-01	Composiciones farmaceuticas que comprenden calcitonina.
FI961494L (fi)	1996-04-03	Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
DE60004093D1 (de)	2003-08-28	Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
ITRM960808A0 (it)	1996-11-26	Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
IT9041714A0 (it)	1990-10-15	Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere
RU2001123675A (ru)	2003-05-10	Средство бальзам "ГРААЛЬ" для лечения сердечно-сосудистой системы и заболеваний крови человека
ES2127133B1 (es)	1999-12-01	Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.

Legal Events

Date	Code	Title	Description
2008-08-15	GB1A	Change in the ownership or in the address of the owner
2013-06-17	GB1A	Change in the ownership or in the address of the owner

EE05492B1 - Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=22475417

Family Applications (1)

Country Status (31)

Families Citing this family (124)

Family Cites Families (203)

Also Published As

Similar Documents

Legal Events

EE05492B1 - Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=22475417

Family Applications (1)

Country Status (31)

Families Citing this family (124)

Family Cites Families (203)

Also Published As

Similar Documents

Legal Events

EE05492B1 - Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral - Google Patents